Interim Tecovirimat (TPOXX) Guidance and Clinical Considerations for Pain Management of Monkeypox: COCA Now: September 21, 2022

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.). Office of Public Health Preparedness and Response. Clinician Outreach and Communication Activity.
• Description:
  The Centers for Disease Control and Prevention (CDC) has updated its Guidance for Tecovirimat (TPOXX) Use Under Expanded Access Investigational New Drug Protocol, based on data from the published literature and recently released data from the Food and Drug Administration, which suggest that broad use of the antiviral drug TPOXX could promote resistance and render the drug ineffective for some patients.
  
  All patients with monkeypox benefit from supportive care and pain control that is started early in the illness. For most patients with healthy immune systems, supportive care and pain control may be enough. However, there are some instances where TPOXX could be beneficial, and CDC has updated guidance to reflect this.
  
  
• Subjects:
  Antiviral Agents Drugs, Investigational Mpox (monkeypox) Poxviridae Infections/drug Therapy Smallpox/drug Therapy
• Series:
  Clinician Outreach and Communication Activity (COCA) Now
• Document Type:
  Text
• Name as Subject:
  Tecovirimat ; Tecovirimat
• Genre:
  Newsletter
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:3a8a1f67904208f5c0a85874586ea2a403b1c9cc9ae24c0a58e4f7ee6f92504cf6a7853d2ac514db7e5a2f5fcb8246198871a381741fb669964e5497fb3382f8
• Download URL:
  https://stacks.cdc.gov/view/cdc/124402/cdc_124402_DS1.pdf
• File Type:
  [PDF - 288.62 KB ]